ELISA: 1/1,000. Western Blot: 1/100 - 1/250. Immunohistochemistry: 1/50 - 1/100. Other applications not tested. Optimal dilutions are dependent on conditions and should be determined by the user.
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Liquid
Konzentration
0.25 mg/mL
Buffer
PBS with 0.09 % (W/V) sodium azide
Konservierungsmittel
Sodium azide
Vorsichtsmaßnahmen
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handhabung
Avoid repeated freezing and thawing.
Lagerung
4 °C/-20 °C
Informationen zur Lagerung
Store the antibody undiluted at 2-8 °C for one month or (in aliquots) at-20 °C for longer.
Target
CTDSP2
(CTD (Carboxy-terminal Domain, RNA Polymerase II, Polypeptide A) Small Phosphatase 2 (CTDSP2))
fb16c04 antikoerper, wu:fb16c04 antikoerper, zgc:77714 antikoerper, MGC68415 antikoerper, CTDSP2 antikoerper, OS4 antikoerper, PSR2 antikoerper, SCP2 antikoerper, AI586070 antikoerper, D10Ertd73e antikoerper, OS-4 antikoerper, CTD (carboxy-terminal domain, RNA polymerase II, polypeptide A) small phosphatase 2 antikoerper, CTD small phosphatase 2 L homeolog antikoerper, CTD small phosphatase 2 antikoerper, ctdsp2 antikoerper, ctdsp2.L antikoerper, CTDSP2 antikoerper, Ctdsp2 antikoerper
Hintergrund
CTDSP2 is one of several small CTD phosphatases (SCP). It has been proposed that SCP activity is an evolutionarily conserved transcriptional regulator that acts globally to silence neuronal genes. In addition, expression of phosphatase CTDSP2 mRNA isenhanced in several cancer cell lines with amplification of the CTDSP2 and CDK4 genes, and CTDSP2 coamplifies with CDK4 in some primary sarcomas. CTDSP2 may contribute to the development of a subset of sarcomas.Synonyms: Carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2, NLI-interacting factor 2, Nuclear LIM interactor-interacting factor 2, Protein OS-4, SCP2, Small CTD phosphatase 2